MarketPulse
H

$HIMS

13 articles found
8 positive
3 negative
2 neutral
BenzingaBenzinga··Vandana Singh

India's Generic Semaglutide Flood Slashes Ozempic Costs by 70%, Reshaping Global Obesity Market

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.
NVOHIMSRDYweight loss drugsobesity market
BenzingaBenzinga··Vandana Singh

Novo Nordisk Wins FDA Nod for High-Dose Wegovy, Expanding GLP-1 Arsenal

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.
NVOHIMSFDA approvalclinical trial
BenzingaBenzinga··Erica Kollmann

Lucid Emerges as Wall Street's Most-Shorted Stock Amid EV Sector Turbulence

Lucid Group tops the most-shorted stocks list as of March 11, 2026, highlighting investor skepticism toward struggling EV manufacturers amid broader market volatility.
MPTSOUNSOUNWIBRXHIMS+6market volatilityshort squeeze
The Motley FoolThe Motley Fool··Dave Kovaleski

Major Asset Manager Exits $18M Hims & Hers Position Ahead of Novo Nordisk Reconciliation

BLKBRD Asset Management fully exits $18M Hims & Hers position in Q4 2025, just before company reconciles with Novo Nordisk.
NVDAGOOGGOOGLNVOHIMSpartnershipweight loss drugs
BenzingaBenzinga··European Capital Insights

European Gas Prices Hit 3-Year High as Geopolitical Tensions Split the Continent

European natural gas surged 68% weekly to 3-year highs amid US-Israeli military actions; weak economic data and political divisions compound energy crisis risks.
NVOHIMSgeopolitical tensionsIran strikes
The Motley FoolThe Motley Fool··Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine
BenzingaBenzinga··Vandana Singh

Hims & Hers Settles Novo Nordisk Patent Dispute, Inks GLP-1 Partnership

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.
NVOHIMSguidance missearnings beat
BenzingaBenzinga··Rishabh Mishra

Stock Futures Tumble as Oil Surges on Iran Tensions; Trump Dismisses Spike

U.S. stock futures tumbled as crude oil surged 13-15% amid Iran tensions. Hims & Hers soared 49% on Novo Nordisk settlement; UniQure gained 36% on FDA clarity.
SPYQQQQURENVOHIMS+3stock market declinecrude oil
The Motley FoolThe Motley Fool··Rich Smith

Hims & Hers Faces Growth Deceleration as GLP-1 Market Dynamics Shift

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.
LLYNVOHIMSearnings reportGLP-1 drugs
Investing.comInvesting.com··Jordan Chussler

Hims Stock Faces Lawsuit Pressure Despite Analyst Optimism on Valuation

Hims stock down 75% due to Novo Nordisk lawsuit over semaglutide marketing, but analysts see 150% upside potential and record revenue coming.
NVOHIMSanalyst-ratingsGLP-1 drugs
BenzingaBenzinga··Caroline Ryan

Wave of Major Acquisitions Reshapes Healthcare, Travel, and Energy Sectors

Major M&A wave reshapes industries: Danaher acquires Masimo for $9.9B, Devon completes $21.4B energy merger, while Starboard pressures TripAdvisor toward sale.
WBDHIMSDHRMCWTRIP+2healthcareprivate equity
BenzingaBenzinga··Vandana Singh

Hims & Hers to Acquire Eucalyptus in $1.15B International Expansion

Hims & Hers to acquire Eucalyptus for $1.15B, expanding into Australia, UK, and Germany. Deal closes mid-2026, marking major international growth push.
NVOHIMSacquisitionM&A
BenzingaBenzinga··Erica Kollmann

Short Interest Surges in Hospitality and EV Stocks Amid Market Skepticism

Short interest surges in hospitality and EV stocks as investors bet against overvalued companies. Choice Hotels, Lucid, and Avis lead with over 48% short positions.
IBRXHIMSCHHLCIDCAR+2market volatilityshort squeeze